Cediranib

Quality 0.50 · 3 views · Updated 2 months ago

Chemical compound

title: "Cediranib" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["receptor-tyrosine-kinase-inhibitors", "indole-ethers-at-the-benzene-ring", "quinazolines", "drugs-developed-by-astrazeneca", "fluoroarenes", "catechol-ethers", "1-pyrrolidinyl-compounds", "experimental-cancer-drugs"] description: "Chemical compound" topic_path: "general/receptor-tyrosine-kinase-inhibitors" source: "https://en.wikipedia.org/wiki/Cediranib" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Chemical compound ::

| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 449572361 | IUPAC_name = 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline | image = Cediranib.svg | image_class = skin-invert-image | tradename = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Oral | bioavailability = | protein_bound = | metabolism = | elimination_half-life = 12 to 35 hours | excretion = | IUPHAR_ligand = 5664 | CAS_number_Ref = | CAS_number = 288383-20-0 | ATC_prefix = L01 | ATC_suffix = EK02 | DrugBank_Ref = | DrugBank = | UNII_Ref = | UNII = NQU9IPY4K9 | PubChem = 9933475 | ChEMBL_Ref = | ChEMBL = 491473 | ChemSpiderID_Ref = | ChemSpiderID = 8109103 | KEGG = D08881 | StdInChI_Ref = | StdInChI = 1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3 | StdInChIKey_Ref = | StdInChIKey = XXJWYDDUDKYVKI-UHFFFAOYSA-N | C=25 | H=27 | F=1 | N=4 | O=3 | smiles = COc4cc3c(Oc2ccc1[nH]c(C)cc1c2F)ncnc3cc4OCCCN5CCCC5 Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.

Clinical trials

Beginning in 2007, it underwent phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment were also undertaken.

On February 27, 2008, AstraZeneca announced that the use of cediranib in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. On 8 March 2010, AstraZeneca issued a press-release stating that cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader bevacizumab. In 2016, AstraZeneca completed a phase III trial comparing the efficacy of cediranib alone and cediranib with lomustine to the efficacy of lomustine alone in patients with recurrent glioblastoma. The trial failed to meet its primary endpoint and survival was not extended with cediranib.

Combination trials

Findings from a federally funded, NCI-sponsored phase II clinical trial presented at the 50th Annual Meeting of the American Society of Clinical Oncology (May 30 - June 3, 2014, Chicago, Ill; Abstract No: LBA5500), show that the combination of two investigational oral drugs, olaparib, a PARP inhibitor, and cediranib is significantly more active against recurrent, platinum chemotherapy-sensitive disease or ovarian cancer related to mutations in BRCA genes than olaparib alone.

References

References

  1. (May 2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Research.
  2. (March 2009). "A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group". European Journal of Cancer.
  3. (June 2008). "The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies". Journal of Thoracic Oncology.
  4. (8 March 2010). "AstraZeneca - RECENTIN did not meet primary endpoint in Horizon III study in metastatic colorectal cancer".
  5. (September 2013). "Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma". Journal of Clinical Oncology.
  6. {{ClinicalTrialsGov. NCT01116648. Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
  7. (October 2014). "Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study". The Lancet. Oncology.
  8. "Combination of Targeted Drugs May Significantly Increase Progression-Free Survival in Women with Recurrent Ovarian Cancer, Study Shows - Onco'Zine - The International Oncology Network; June 2, 2014".

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::

receptor-tyrosine-kinase-inhibitorsindole-ethers-at-the-benzene-ringquinazolinesdrugs-developed-by-astrazenecafluoroarenescatechol-ethers1-pyrrolidinyl-compoundsexperimental-cancer-drugs